Medical Pharmacology Chapter 29 Diabetes Management Practice Questions

Choose the correct statement(s):
1. Reduction in glucose levels has been shown to be definitely associated with a decrease in the rate of cardiovascular "events" and death.
2. The combination of type 2 diabetes and cardiovascular disease increases death risk.
3. Both
4. Neither
Aggressive glucose lowering or administration a specific glucose-lowering drugs might be associated with adverse cardiovascular outcomes.
1. True
2. False
Principal mechanism of action of sodium-glucose cotransporter 2:
1. Reduction in rate of glomerular filtration.
2. Reduction in renal glucose reabsorption.
3. Both
4. Neither
Empagliflozin (Jardiance) is a selective inhibitor of sodium glucose cotransporter 2.
1. True
2. False
Empagliflozin (Jardiance) has been approved for management of type 2 diabetes.
1. True
2. False
Empagliflozin administration either as monotherapy or as an adjunct agent:
1. Appears to decrease glycated hemoglobin in patients with type 2 diabetes.
2. Appears associated with both weight loss and a reduction in blood pressure without a compensatory increase in heart rate.
3. Both
4. Neither
Most common side effects of empagliflozin administration:
1. Genital infection
2. Urinary tract infection
3. Both
4. Neither
Which one of the following drugs is categorized as an SGLT2 inhibitor?
1. Lixisenatide
2. Canagliflozin
3. Pramlintide
4. Rosiglitazone
Administration of which one of the following type 2 diabetes medications is the most likely to result in weight gain?
1. Sulfonylureas (2nd generation)
2. Metformin
3. SGLT2 inhibitors
4. Thiozolidinediones
Administration of which one of the following is most likely to predisposed to heart failure or worsen existing heart failure?
1. GLP-1 RAs
2. 2nd generation sulfonylureas
3. Metformin
4. Rosiglitazone (Thiozolidinediones)